XML 130 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Other (Income) Expense, Net
 12 Months Ended
Dec. 31, 2019
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Years Ended December 31
2019
 
2018
 
2017
Interest income
$
(274
)
 
$
(343
)
 
$
(385
)
Interest expense
893

 
772

 
754

Exchange losses (gains)
187

 
145

 
(11
)
Income from investments in equity securities, net (1)
(170
)
 
(324
)
 
(352
)
Net periodic defined benefit plan (credit) cost other than service cost
(545
)
 
(512
)
 
(512
)
Other, net
48

 
(140
)
 
6

 
$
139

 
$
(402
)
 
$
(500
)

(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Other, net (as presented in the table above) in 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8).
Other, net in 2018 includes a gain of $115 million related to the settlement of certain patent litigation, income of $99 million related to AstraZeneca’s option exercise in 2014 in connection with the termination of the Company’s relationship with AstraZeneca LP (AZLP), and a gain of $85 million resulting from the receipt of a milestone payment for an out-licensed migraine clinical development program. Other, net in 2018 also includes $144 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8), as well as $41 million of charges related to the write-down of assets held for sale to fair value in anticipation of the dissolution of the Company’s joint venture with Supera Farma Laboratorios S.A. in Brazil.
Other, net in 2017 includes income of $232 million related to AstraZeneca’s option exercise and a $191 million loss on extinguishment of debt.
Interest paid was $841 million in 2019, $777 million in 2018 and $723 million in 2017.